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Introduction: CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell
autoimmune responses. The CAD106 first-in-human study demonstrated a favorable safety profile and promising
antibody response. We investigated long-term safety, tolerability and antibody response after repeated CAD106 injections.
Methods: Two phase IIa, 52-week, multicenter, randomized, double-blind, placebo-controlled core studies (2201; 2202) and
two 66-week open-label extension studies (2201E; 2202E) were conducted in patients with mild Alzheimer’s disease (AD)
aged 40 to 85 years. Patients were randomized to receive 150μg CAD106 or placebo given as three subcutaneous (2201) or
subcutaneous/intramuscular (2202) injections, followed by four injections (150 μg CAD106; subcutaneous, 2201E1;
intramuscular, 2202E1). Our primary objective was to evaluate the safety and tolerability of repeated injections,
including monitoring cerebral magnetic resonance imaging scans, adverse events (AEs) and serious AEs (SAEs).
Further objectives were to assess Aβ-specific antibody response in serum and Aβ-specific T-cell response (core only).
Comparable Aβ-immunoglobulin G (IgG) exposure across studies supported pooled immune response assessments.
Results: Fifty-eight patients were randomized (CAD106, n = 47; placebo, n = 11). Baseline demographics and
characteristics were balanced. Forty-five patients entered extension studies. AEs occurred in 74.5% of CAD106-treated
patients versus 63.6% of placebo-treated patients (core), and 82.2% experienced AEs during extension studies. Most AEs
were mild to moderate in severity, were not study medication-related and did not require discontinuation. SAEs
occurred in 19.1% of CAD106-treated patients and 36.4% of placebo-treated patients (core). One patient
(CAD106-treated; 2201) reported a possibly study drug-related SAE of intracerebral hemorrhage. Four patients
met criteria for amyloid-related imaging abnormalities (ARIA) corresponding to microhemorrhages: one was
CAD106-treated (2201), one placebo-treated (2202) and two open-label CAD106-treated. No ARIA corresponded
to vasogenic edema. Two patients discontinued extension studies because of SAEs (rectal neoplasm and rapid
AD progression, respectively). Thirty CAD106-treated patients (63.8%) were serological responders. Sustained Aβ-IgG
titers and prolonged time to decline were observed in extensions versus core studies. Neither Aβ1–6 nor Aβ1–42 induced
specific T-cell responses; however, positive control responses were consistently detected with the CAD106 carrier.
Conclusions: No unexpected safety findings or Aβ-specific T-cell responses support the CAD106 favorable tolerability
profile. Long-term treatment-induced Aβ-specific antibody titers and prolonged time to decline indicate antibody
exposure may increase with additional injections. CAD106 may be a valuable therapeutic option in AD.
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Alzheimer’s disease (AD) is the most common cause of de-
mentia in elderly populations, with an estimated worldwide
prevalence of 35.6 million individuals in 2010, a number
expected to almost quadruple by 2050 [1]. The global eco-
nomic cost of the disease is huge and was estimated in
2010 to total US$604 billion [2]. Current management of
AD involves symptomatic treatment with cholinesterase
inhibitors (ChEIs), N-methyl-D-aspartate receptor partial
antagonists and other drugs used to treat secondary
behavioral symptoms associated with the illness [3,4].
Increased understanding of the pathogenesis of AD has
identified a key role for amyloid-β (Aβ) peptide deposits
in the development of AD [5]. Blocking aggregation of Aβ
peptides and reducing Aβ plaque burden using disease-
modifying immunotherapies is a promising approach in
the treatment of AD [5-13]. However, recent phase III trial
results of using monoclonal antibodies targeting Aβ have
demonstrated equivocal evidence for efficacy in patients
with mild-to-moderate AD [14,15], although clinical
studies with solanezumab in patients with mild AD are
continuing [14].
In a phase II trial of an active immunotherapy antibody
to full-length Aβ peptide (AN1792 protein given with the
adjuvant QS-21), researchers reported meningoencephal-
itis in a subset of patients, which led to concerns regarding
T-cell activation [16]. In contrast, the novel, active im-
munotherapy CAD106 is targeted against a small peptide
fragment of Aβ (Aβ1–6) and is conjugated to a carrier (Qβ
bacteriophage). CAD106 is designed to ensure repetitive
antigen (Aβ1–6) presentation and strong B-cell response,
stimulating the generation of Aβ-specific antibodies while
avoiding initiation of Aβ-specific T-cell responses [11].
Preclinical evidence suggests that CAD106 is capable of
reducing Aβ accumulation in the brain by inducing anti-
bodies that interfere with amyloid deposition and by binding
to Aβ aggregates [11]. Following these positive preclinical
findings [11], researchers in the first-in-human CAD106
study (CCAD106A2101; NCT00411580) investigated safety,
tolerability and Aβ-specific antibody response following
three subcutaneous (s.c.) injections of CAD106 or placebo
in patients with mild-to-moderate AD [17]. The findings
from that study suggested that three injections of CAD106
(50 or 150 μg) have a favorable safety profile and are capable
of eliciting promising antibody responses without inducing
autoimmune reactions [17]. In that study, total plasma Aβ
concentration increased, whereas free Aβ in plasma
decreased, indicating in vivo binding of antibodies to
Aβ. Furthermore, CAD106-induced antibodies were cap-
able of reacting with amyloid plaque cores and Aβ
oligomers ex vivo [18].
We report the findings from two phase IIa, 52-week,
multicenter, randomized, double-blind, placebo-controlled,
parallel-group (core) studies of CAD106 and, following a4-week rescreening period, their respective 66-week open-
label extension studies (Figure 1). The objectives of these
studies were to investigate safety and tolerability of re-
peated injections of 150μg CAD106 and evaluate anti-
body response following different dosing regimens in
patients with mild AD dementia over a total duration
of 122 weeks.
Methods
Study protocols and amendments were reviewed by the
independent ethics committee or institutional review
board for each center (see Additional file 1). Studies
were conducted according to the ethical principles of
the Declaration of Helsinki.
Patients
Patients were enrolled into the core studies in France,
Sweden, Switzerland and the United Kingdom (CCAD
106A2201; NCT00733863) and in the United States
(CCAD106A2202; NCT00795418). Informed consent was
obtained from each patient in writing before randomization.
Inclusion and exclusion criteria for the core studies were
identical. Patients were male or female (not of childbearing
potential), aged 40 to 85 years and had a diagnosis of
AD according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition [19] and probable AD
according to the Work Group of the National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders Asso-
ciation [20]. At the time of study entry, patients were
required to have mild AD (Mini Mental State Examination
(MMSE) score 20 to 26), be untreated or on a stable dose
(previous 6 weeks) of ChEI or other AD treatment, and to
be in at least daily contact with a primary caregiver. Exclu-
sion criteria included other medical or neurological condi-
tions contributing significantly to the patient’s dementia; a
history (past 2 years) or current diagnosis of central nervous
system (CNS) inflammation indicative of meningoencephal-
itis or another immune disorder; a history of clinical stroke,
intracranial hemorrhage or aneurysm; current diagnosis of
significant cerebrovascular disease; and evidence of more
than two cerebral microhemorrhages identified by a
magnetic resonance imaging (MRI) central reader.
Patients who completed the core studies without major
safety concerns were eligible for inclusion in the exten-
sion studies (CCAD106A2201E1, NCT00956410; and
CCAD106A2202E1, NCT01023685). Patients who de-
veloped any condition listed in the core study exclu-
sion criteria or who developed further conditions, such
as neurodegenerative or psychiatric disorders, were
excluded from the extension studies.
Patients required discontinuation from core or exten-
sion studies in the event of: development of two or more
new brain microhemorrhages, meningoencephalitis or
Figure 1 Overall study design: core and extension studies. *Not included in these analyses. †Not suspected to be related to study drug.
AE, Adverse event; N, number of patients in treatment group; n, Number of patients with a measurement; SAE, Serious adverse event.
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findings of concern, moderate-to-severe symptomatic
neurological abnormalities or unexpected worsening of
dementia, or severe local or systemic reaction to the first
or second injection.
Patient safety was monitored by an independent Data
Monitoring Committee (DMC) who applied prespecified cri-
teria listed in the protocols for suspension of immunization
in specific individuals of concern or in all patients.
Randomization and masking
Patients who met the core study eligibility criteria during
the 3-week screening period were randomized (4:1; blockedby center) to receive CAD106 (150 μg) or placebo.
The randomization list was generated at Novartis.
(Basel, Switzerland) Identity of treatment was con-
cealed for all study participants and personnel, with the
exception of pharmacists handling study medication,
members of the DMC, and the designated unblinded inde-
pendent study team members.
Study design and procedures
Dose selection and dosing schedule were based on the
phase I study [17]. In study 2201, three injections were
given s.c., at Weeks 0, 6 and 12. In study 2202, each patient
received three injections either s.c. or by intramuscular
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label extension studies, all patients received four injec-
tions of CAD106 150 μg at 12-week intervals (s.c. in
2201E1; i.m. in 2202E1) (Figure 1).
Study objectives and outcomes
The primary objective was to evaluate the safety and toler-
ability of repeated injections of CAD106 150 μg in patients
with mild AD over the course of 52 weeks and following a
66-week open-label extension. Further objectives included
(1) determination of Aβ-specific antibody response to
CAD106 (Aβ-immunoglobulin G (IgG) in serum and
cerebrospinal fluid (CSF)) and increase in plasma Aβ1–40
from baseline, (2) characterization of Aβ-specific (Aβ1–6
and Aβ1–42) and Qβ-induced (as a positive control) T-cell
responses in peripheral blood mononuclear cells (PBMCs;
core studies only), (3) exploration of potential treatment
effect on disease-related biomarkers in CSF and (4)
exploration of potential treatment effects on disease
progression as measured by volumetric cerebral MRI
and clinical assessments.
Assessments
All data were recorded on an electronic Case Report
Form during core and extension studies.
Safety and tolerability outcomes were monitored through-
out the studies and were assessed by performing general
physical examinations, neurological examinations, 12-lead
electrocardiography (ECG), vital sign measurements, labora-
tory evaluations in blood and CSF, cerebral MRIs and ad-
verse event (AE) and serious AE (SAE) monitoring. Patients
or their caregivers were instructed to record details of local
and systemic injection-related reactions in a diary over a 7-
day period following each injection. MRI was performed at
screening, three times post-baseline during the core studies
(Weeks 10, 20 and 52 (2201); Weeks 14, 26 and 52 (2202))
and three times during the extension studies (Weeks 74,
100 and 122). Lumbar punctures were scheduled at screen-
ing, at Weeks 20 (2201) and 14 (2202) and optionally at
Weeks 96 and 122 (2201E and 2202E). Antibody titers and
AD biomarkers were measured at those different CSF
sampling time points. Antigen-specific T-cell assays
(enzyme-linked immunospot) were performed on PBMC
samples obtained at screening and 2 weeks after the second
and third injections in the core studies only.
Cerebral MRI findings at screening and newly occurring
findings were assessed by an independent central radiolo-
gist. Examinations were conducted using 1.5-T scanners,
with harmonized setup across centers, to detect white
matter lesions, microhemorrhages (amyloid-related im-
aging abnormalities (ARIA) corresponding to microhe-
morrhages (ARIA-H)), edema and inflammation, and
included the following image sequences: fluid-attenuated in-
version recovery (FLAIR; ARIA corresponding to vasogenicedema (ARIA-E)); T2-weighted scans, T2*-weighted
gradient echo scans (microhemorrhages), diffusion-
weighted imaging (to diagnose vascular pathology and
differentiate between vasogenic and cytotoxic edema)
and T1-weighted scans (volumetric MRI).
Aβ-specific antibody titers in serum were measured
using an enzyme-linked immunosorbent assay at each
scheduled visit from screening until the end of the study,
as described previously [21]. Antibody titers were expressed
in units in reference to rhesus monkey reference serum to
allow comparison across CAD106 studies. Total plasma
Aβ1–40 (free and bound) levels were measured using a
Meso Scale Discovery (MSD)-based assay (catalog number
K150FTE-3; Meso Scale Diagnostics, Rockville, MD, USA)
and were compared with baseline levels. This assay utilizes
combination capture with anti-Aβ1–40 targeted at the N-
terminal domain of Aβ1–40 and ruthenium-labeled detec-
tion monoclonal antibody (4G8). The assay was validated
and adapted for semiquantification of longitudinal changes
in Aβ1–40 in human plasma only. Additional analyses were
performed on selected patients’ samples to determine Aβ-
IgG affinity maturation during core study 2201.
Aβ- and Qβ-induced T-cell responses were assessed
based on interferon-gamma (IFN-γ) cytokine. Antigen-
specific T-cell response was determined by the number
of cells secreting IFN-γ, comparing cell number from
non-stimulated wells (C; in medium) with cell number
from antigen-stimulated wells (R). Mean number of cells
(standard deviation (SD)) was based on three replicate
experiments. Antigen-specific T-cell response was derived
at each visit as ((mean (R) − SD (R)) − (mean (C) + SD (C))),
and mean change (SD) from baseline in T-cell response was
assessed at each visit.
Disease-related biomarkers in CSF comprised Aβ1–40 and
Aβ1–42, total tau and hyperphosphorylated tau (phospho-
tau). An MSD-based sandwich assay was used to measure
the concentration of Aβ1–40 and Aβ1–42. Concentration of
total tau and phospho-tau181 were measured by solid-phase
enzyme immunoassay using kits provided by Fujirebio
Europe (Gent, Belgium).
The effect of CAD106 on brain volume (measured in
cm3) was calculated using a T1-weighted MRI scan, per-
formed as part of the safety cerebral MRI. T1-weighted
images were analyzed under supervision of the Novartis
Clinical Imaging Unit using NeuroQuant software
(CorTechs Labs, La Jolla, CA, USA) to identify and com-
pute the volume of whole brain and its substructures
(hippocampus, cerebral cortex, white matter and
ventricles). The clinical assessments MMSE, Global
Deterioration Scale, Alzheimer’s Disease Assessment
Scale–Cognitive subscale (ADAS-Cog; 11 items), Trail
Making Test Part A and category fluency were conducted
by qualified personnel not involved in safety assessments.
Caregiver completion of the Alzheimer’s Disease
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psychiatric Inventory Questionnaire was performed under
guidance of a study nurse or neuropsychologist.
Statistical analysis
Sample size for the core studies was calculated based on
the likelihood of detecting a 6% event rate for meningo-
encephalitis, as seen in the AN1792 study [16]. Twenty-
four patients on active treatment was considered sufficient;
the probability of observing at least one case of meningo-
encephalitis with a true incidence rate of 6% was calculated
to be 77.3%.
A pooled approach combining the two studies and
their respective extensions, with up to seven injections
in total through 122 weeks, was planned to enhance the
chances of detecting any signal on safety outcome mea-
sures. The two studies were designed in parallel with
similar features, with the exception of schedule of injec-
tions in the core studies and the route of administration.
As the actual exposure to Aβ-IgGs was found to be
comparable in the two studies (see Results), this pooled
approach was used.
Analyses were based on pooled study data unless
otherwise stated. All patients who received at least one
injection and had at least one post-injection safety as-
sessment were included in the pooled safety analysis set.
The analyses presented here are based on this analysis
set. For immune response and pharmacodynamic assess-
ments, reports focus on patients in the pooled safety
analysis set who were randomized to CAD106 in the
core studies (that is, received CAD106 throughout the
core and extension studies). Descriptive group comparisons
were predominantly of patients who received CAD106
versus placebo during the core studies.
Patients treated with CAD106 were classified as sero-
logical responders or non-responders based on serum
Aβ-IgG titers during the core studies. The lower limit of
quantification (LLOQ) of serum Aβ-IgG titers was deter-
mined as 8.93 U based on assay variability and baseline
titers observed in the phase I CAD106 study [17]. The
responder threshold was increased after learnings from
the 2201E and 2202E extension studies were imple-
mented. Serological responders were defined as demon-
strating a consistent antibody response after the second
and third injections: Aβ-IgG titers above 16 U between
the second and third injections and above 26.8 U after
the third injection. The threshold of 16 U corresponds
to the LLOQ plus three times the SD, and the threshold
of 26.8 U corresponds to three times the LLOQ. Anti-
body response was characterized by the area under the
titer curve (AUC), calculated using the trapezoidal
method for observed data.
Change from baseline in phospho-tau in CSF was ana-
lyzed by using a mixed-effects repeated measurementmodel, adjusted for phospho-tau baseline value and in-
cluding visit week and the interaction as repeated
factors.
Results
Patients
Fifty-eight patients were randomized and exposed to
study drug during the core studies: 47 to CAD106 and
11 to placebo. Forty-five patients entered the extension
studies and received open-label treatment (CAD106).
Details of patient flow and disposition through the stud-
ies are shown in Figure 1. All but two patients received
three scheduled injections during the core studies. In
the extension studies, all patients received at least two
injections of CAD106; 19 patients (90.5%) in 2201E re-
ceived all four injections. In 2202E, only 13 patients
(54.2%) received the scheduled four injections. Eight pa-
tients (33.4%) did not receive the fourth injection, owing to
temporary suspension of CAD106 dosing during the evalu-
ation of an SAE (subdural hematoma followed by intrace-
rebral hemorrhage (ICH)), initially suspected to be
related to study drug in another study with CAD106.
Baseline (core study) demographics and disease char-
acteristics were generally well balanced between patients
randomized to receive CAD106 versus placebo, although
patients in the CAD106 pooled group were, on average,
2 years older and less frequently apolipoprotein E4 allele
(ApoE4) carriers (60% versus 82%). There were no not-
able differences in MMSE scores between groups, with
mean scores of approximately 22 (Table 1).
Safety and tolerability
During the core studies, AEs occurred in 35 patients
(74.5%) treated with CAD106 and seven patients (63.6%)
who received placebo. In the extension studies, the
majority of patients reported at least one AE over the
66-week duration, although no unexpected safety find-
ings were noted. Across the studies, most AEs were
considered mild or moderate in severity, were not re-
lated to study drug and did not require study drug
interruption. There were no differences in the severity
of AEs or causality between groups.
The most frequently observed AEs in patients treated
with CAD106 during the core studies were spread across
multiple system organ classes; no specific pattern for inci-
dence of AEs was detected (Table 2). The main categories
of AEs with an increased incidence with CAD106 versus
placebo included nervous system disorders (21.3%; the
most frequent AE being headache (12.8%)) and general
disorders and administration site conditions (29.8%; the
most frequent AE being pyrexia (8.5%)).
Imbalance for cardiac disorders was observed during
the core studies, with AEs reported in six patients
(12.8%) who received CAD106 versus no patients who
Table 1 Patient demographics and core baseline disease characteristics by treatment (pooled safety analysis set)
CAD106 (2201) CAD106 (2202) CAD106 (total) Placebo (total)
N = 22 N = 25 N = 47 N = 11
Sex, n (%)
Male 14 (63.6) 15 (60.0) 29 (61.7) 6 (54.5)
Female 8 (36.4) 10 (40.0) 18 (38.3) 5 (45.5)
Age (yr)
Mean (SD) 65.6 (7.1) 70.5 (8.7) 68.2 (8.2) 66.3 (6.9)
Age group, n (%)
<65 yr 10 (45.5) 6 (24.0) 16 (34.0) 6 (54.5)
65–75 yr 10 (45.5) 9 (36.0) 19 (40.4) 4 (36.4)
>75 yr 2 (9.1) 10 (40.0) 12 (25.5) 1 (9.1)
Race, n (%)
Caucasian 22 (100.0) 24 (96.0) 46 (97.9) 10 (90.9)
Black 0 (0.0) 1 (4.0) 1 (2.1) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1)
Years of education
Mean (SD) 11.7 (2.7) 14.2 (3.2) 13.1 (3.2) 12.2 (4.1)
MMSE score at baseline
Mean (SD) 23.1 (2.2) 21.9 (1.9) 22.5 (2.1) 22.8 (2.3)
Time since first symptom of AD was noticed by patient/caregiver (yr)
Mean (SD) 5.4 (2.7) 3.3 (2.2) 4.3 (2.6) 4.5 (1.8)
Time since first symptom of AD was first diagnosed by physician (yr)
Mean (SD) 2.0 (1.7) 1.3 (1.3) 1.6 (1.5) 1.8 (1.3)
ApoE4 carrier status, n (%)*
Missing 2 (9.1) 2 (8.0) 4 (8.5) 1 (9.1)
Non-ApoE4 9 (40.9) 3 (12.0) 12 (25.5) 1 (9.1)
One ApoE4 8 (36.4) 15 (60.0) 23 (48.9) 5 (45.5)
Two ApoE4 3 (13.6) 5 (20.0) 8 (17.0) 4 (36.4)
AD, Alzheimer’s disease; ApoE4, Apolipoprotein E4 allele; MMSE, Mini Mental State Examination; N, Number of subjects in treatment group; n, Number of patients
with a measurement; SD, Standard deviation. *Percentage based on the number of patients genotyped.
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(15.6%) reported cardiac disorders; four of these patients
had previously reported such events during the core
studies. Of the nine patients with cardiac disorders, two
patients required hospitalization: one for myocardial is-
chemia along with an AE of coronary artery stenosis,
and one for complete atrioventricular block. In addition,
four patients reported rhythm disturbances (bradycardia
(n = 2), ventricular extrasystoles (n = 1), tachycardia
(n = 1)), two reported cardiac perfusion-related AEs
(angina pectoris, arteriosclerosis coronary artery) and
one experienced left ventricular hypertrophy.
There were no incidences of meningoencephalitis, auto-
immune disease or CNS inflammation, as confirmed by
CSF laboratory assessments and regular MRI scans. No
relevant findings were reported on ECGs, vital signs mea-
surements or standard laboratory evaluations in patientstreated with CAD106 or placebo. There was no increase in
white blood cell count in CSF and no abnormalities in al-
bumin or total IgG CSF : blood indices. Increase in oligo-
clonal bands in CSF only, with no concomitant signs or
symptoms, was detected in two (9.1%) CAD106-treated pa-
tients during core study 2201.
Across the two core and extension studies, one patient
died during the open-label extension study 2202E. The
death was not considered to be related to study medica-
tion (progression of chronic obstructive pulmonary dis-
ease). There was no imbalance of SAEs during the core
studies across treatment groups. Of the 13 reported
SAEs, a single case of ICH was assessed by the investiga-
tor as potentially related to CAD106 during core study
2201. After receiving the three scheduled injections of
CAD106, the patient did not meet the responder criteria
and had last detectable Aβ-IgG at week 16 (12.6 U).
Table 2 Summary of deaths, serious adverse events, discontinuations due to serious adverse events, and adverse
events, regardless of study drug relationship (core and extension studies; pooled safety analysis set)
Core studies Extension studies
CAD106 (2201) CAD106 (2202) CAD106 (pooled) Placebo (pooled) CAD106 total (pooled)
N = 22 (all s.c.) N = 25 (n = 9 s.c.; n = 16 i.m.) N = 47 N = 11 N = 45
Deaths 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
SAEs 4 (18.2) 5 (20.0) 9 (19.1) 4 (36.4) 6 (13.3)
Intracerebral hemorrhage 1 (4.5)** 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0)
Discontinuations due to (S)AEs 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.4)
Amyloid-related imaging
abnormalities*
1 (4.5) 0 (0.0) 1 (2.1) 1 (9.1) 2 (4.4)
With hemorrhage 1 (4.5)** 0 (0.0) 1 (2.1) 1 (9.1) 2 (4.4)
Any primary system organ
class, n (%)
15 (68.2) 20 (80.0) 35 (74.5) 7 (63.6) 37 (82.2)
Cardiac disorders 3 (13.6) 3 (12.0) 6 (12.8) 0 (0.0) 7 (15.6)
Gastrointestinal disorders 6 (27.3) 2 (8.0) 8 (17.0) 2 (18.2) 15 (33.3)
Diarrhea 3 (13.6) 0 (0.0) 3 (6.4) 0 (0.0) 6 (13.3)
General disorders and
administration site
conditions
6 (27.3) 8 (32.0) 14 (29.8) 2 (18.2) 9 (20.0)
Pyrexia 1 (4.5) 3 (12.0) 4 (8.5) 1 (9.1) 0 (0.0)
Fatigue 1 (4.5) 2 (8.0) 3 (6.4) 1 (9.1) 6 (13.3)
Infections and infestations 8 (36.4) 3 (12.0) 11 (23.4) 3 (27.3) 16 (35.6)
Nasopharyngitis 2 (9.1) 0 (0.0) 2 (4.3) 0 (0.0) 6 (13.3)
Injury, poisoning and procedural
complications
0 (0.0) 5 (20.0) 5 (10.6) 2 (18.2) 9 (20.0)
Fall 0 (0.0) 3 (12.0) 3 (6.4) 1 (9.1) 3 (6.7)
Investigations 4 (18.2) 2 (8.0) 6 (12.8) 2 (18.2) 4 (8.9)
Musculoskeletal and connective
tissue disorders
6 (27.3) 3 (12.0) 9 (19.1) 1 (9.1) 9 (20.0)
Back pain 1 (4.5) 3 (12.0) 4 (8.5) 0 (0.0) 3 (6.7)
Nervous system disorders 4 (18.2) 6 (24.0) 10 (21.3) 2 (18.2) 11 (24.4)
Headache 2 (9.1) 4 (16.0) 6 (12.8) 0 (0.0) 6 (13.3)
Psychiatric disorders 2 (9.1) 6 (24.0) 8 (17.0) 4 (36.4) 15 (33.3)
Confusional state 0 (0.0) 3 (12.0) 3 (6.4) 0 (0.0) 3 (6.7)
Depression 1 (4.5) 2 (8.0) 3 (6.4) 0 (0.0) 6 (13.3)
Renal and urinary disorders 2 (9.1) 4 (16.0) 6 (12.8) 1 (9.1) 4 (8.9)
Skin and subcutaneous
tissue disorders
0 (0.0) 6 (24.0) 6 (12.8) 1 (9.1) 7 (15.6)
AE, Adverse event; ARIA-E, Amyloid-related imaging abnormalities corresponding to vasogenic edema; ARIA-H, Amyloid-related imaging abnormalities corresponding
to microhemorrhage; FLAIR, Fluid-attenuated inversion recovery; ICH, Intracerebral hemorrhage; i.m., Intramuscular; N, Number of patients in treatment group; n,
Number of patients reporting event; SAE, Serious adverse event; s.c., Subcutaneous; SOC, System organ class. *ARIA-H include two or more new microhemorrhages,
subarachnoid hemorrhages or hemosiderosis. No ARIA-E findings were reported. One patient with T2-weighted FLAIR at Week 52 was confirmed as ischemic stroke at an
unscheduled scan (Week 56 extension baseline), ruling out the likelihood of vasogenic edema. **The same patient experienced subarachnoid hemorrhage at Week 20 and
ICH at Week 36. SOCs are presented in alphabetical order for incidences >10% in any CAD106 treatment group. Within each SOC, preferred terms for AEs with an
incidence >10% in any CAD106 treatment group are shown. A subject with multiple occurrences of an AE under one treatment is counted only once in
each AE category for that treatment. A subject with multiple AEs within a SOC or preferred term is counted only once in the total row for the core and
extension studies. Ongoing events at the end of the core study are counted again in the extension studies; therefore, patients may be counted twice in the
total columns for the core and extension studies.
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fied on the scheduled MRI at week 20, and an ICH was
diagnosed during an unscheduled MRI at week 36, con-
ducted after the patient experienced word-finding difficultiesand disorientation. A relationship to study drug was consid-
ered possible by the investigator. The patient completed the
core study safety monitoring until Week 52, but was
not eligible to continue in the extension.
Farlow et al. Alzheimer's Research & Therapy  (2015) 7:23 Page 8 of 13During the extension studies, two patients discontinued
as a result of SAEs (SAEs of rectal neoplasm (2201E) and
rapid AD progression (2202E)).
During the core studies, two patients presented with
findings meeting ARIA-H criteria: one placebo-treated
patient (9.1%) presented with two or more new microhe-
morrhages (2202), and one CAD106-treated patient (2.1%)
presented with subarachnoid hemorrhage (2201; the
same patient who reported SAE of ICH). During the exten-
sion studies, two further patients (4.3%) presented with
two or more new microhemorrhages. All four patients
across the studies remained asymptomatic. The three
CAD106-treated patients were carriers of one ApoE4 allele,
whereas the placebo-treated patient was a non-carrier.
Only one of the CAD106-treated patients (with a finding
of at least two new microhemorrhages during the exten-
sion) met the criteria for being a serological responder.
No MRI findings compatible with ARIA-E criteria were
reported. One asymptomatic case of new hyperintense
T2-weighted lesion (CAD106-treated patient (2202)) at
Week 52 was confirmed as related to a small cortical
infarction (stroke) upon repeat MRI.
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(myalgia), joint pain (arthralgia), headache, sweating, fatigue. i.m., Intramusculasystemic reactions (such as flu-like symptoms, fever, head-
ache, fatigue, chills or muscular pain), were observed in
the majority of patients receiving CAD106. The reactions
were mostly mild to moderate and did not require treat-
ment. None of the reactions led to discontinuation of
injections. In one case, a patient experienced transient
systemic reactions (syncope) associated with the second
and third injections in the core study (2202; s.c. route)
that were suspected to be related to study drug. This pa-
tient entered the extension study and received the fourth
injection (first injection of extension) under supervision at
the hospital. All four injections in the extension study
were well tolerated, and there were no further reports of
similar systemic reactions in this patient. During the core
studies, tolerability with the i.m. route of injection (2202)
was comparable with the s.c. route (2201 and part of study
2202) (Figure 2). The i.m. route of injection was found to
result in fewer local reactions across all injections and in
fewer systemic reactions with the third injection.
Antibody response
No patient presented with serum Aβ-IgG titers above
the LLOQ at baseline. Patients randomized to placebo
did not develop Aβ-IgG titers during the core studies. TheInjection 3 Any
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welling, local pain. Systemic reactions: fever, chills, malaise, muscle pain
r; s.c., Subcutaneous.
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and peak value in serum) were similar across the core
studies, but showed high variability between individual pa-
tients (Figure 3A). In core study 2202, patients received
CAD106 via s.c. or i.m. route of administration. Patients
who received i.m. injections generally showed a higher re-
sponse (n = 15, mean AUC= 11,107.13 U/day) than those
who received CAD106 by s.c. administration (n = 9, mean
AUC = 4,743.5 U/day). No difference was observed be-
tween s.c. (2201E1) versus i.m. (2202E1) administration
routes in the extension studies.
Sustained Aβ-IgG titers above the serological responder
threshold were observed between consecutive injec-
tions in the extension studies, with almost 50% of pa-
tients maintaining Aβ-IgG titers above the threshold at
the end of the study (30 weeks after last injection of
CAD106; median 23.4 U and 24.0 U for 2201E and
2202E, respectively). A prolonged time to decline in anti-
body titers was detected in the extension studies com-
pared with the core studies for patients who received
CAD106 during the core and extension studies. Of those
patients treated with CAD106 during the core studies, 30
(63.8%) were considered serological responders. Placebo
patients who continued in the extension and received
open-label treatment with CAD106 reached similar
Aβ-IgG titers as observed in CAD106-treated patients
during the core studies (data not shown).
The total concentration of plasma Aβ1–40 (free and
bound fractions) in the periphery was expected to in-
crease upon binding to Aβ-IgGs. As shown in Figure 3B,
total plasma Aβ1–40 increased with repeated injections of
CAD106. In the extension studies, the range of plasma
Aβ1–40 concentrations was much larger than in the core
studies, with the upper quartile of plasma Aβ1–40 distribu-
tion reaching a tenfold increase compared with baseline
concentrations. At the same time points, the upper quar-
tile of Aβ-IgG titers increased by approximately twofold.
No increase in plasma Aβ1–40 was seen in placebo-treated
patients. The concentration of plasma Aβ1–40 correlated
with the AUC of Aβ-IgGs, with Spearman’s correlation
coefficients of 0.70 after the third injection (Week 20
for study 2201; Week 14 for study 2202) and 0.60 after
the seventh injection (Week 96 of both studies).
The apparent maturation of affinity of CAD106-
generated Aβ-specific antibodies was determined in
two samples from study 2201, collected at Week 8
(two weeks after second injection) and Week 14 (two
weeks after third injection), respectively. Representative
patients showing a serological response were selected, and
their samples were compared with an Aβ1–6 monoclonal
antibody control. The affinity profiles demonstrated wide
polyclonal distribution of Aβ-specific antibody response,
with a notable improvement in overall apparent affinity of
response between Weeks 8 and 14, with a subpopulationof antibodies reaching nanomolar affinity (Kd) for Aβ1–6 at
Week 14 (Figure 3C).
At each lumbar puncture, all patients who contributed
CSF samples were also tested for Aβ-IgGs in CSF. Only
two of the 47 CAD106-treated patients had quantifiable
Aβ-IgGs in CSF; both patients had high serum Aβ-IgGs
at the same time points. One patient had CSF IgG titer
of 2.87 U and serum level of 1,240 U (2201E1 at Week
96), and the other had a CSF IgG titer of 1.13 U and
serum level of 260 U (2202 at Week 14). These titers
yield a CSF : serum ratio of antibodies close to 0.2%.
T-cell response
A Qβ-induced T-cell response (change from baseline in
IFN-γ-secreting cell numbers) was consistently detected
in patients treated with CAD106. Mean change from
baseline (SD) in Qβ-induced T-cell response increased
with injections and reached a maximum 2 weeks after
the third injection in both studies (Week 14 (2201) =
31.0 (48.95) and Week 8 (2202) = 39.2 (67.34), respect-
ively). No change was observed at any time point with
Aβ1–6 or Aβ1–42 in patients treated with placebo. Neither
Aβ1–6 nor Aβ1–42 induced any specific T-cell responses.
The number of T cells secreting IFN-γ remained stable
up to 2 weeks after the third injection. Induction levels
were −7.5 (32.17) and 0.6 (5.98) at Week 14 (2201) and
−0.5 (0.87) and 0.0 (0.89) at Week 8 (2202) for Aβ1–42 and
Aβ1–6, respectively.
Pharmacodynamic results
In general, concentrations of disease-related biomarkers
were comparable between treatment groups at core
study baseline. Overall in the core studies, no treatment
effect was observed on any CSF disease-related markers
with CAD106 versus placebo at the early CSF time point
of 8 weeks after the third injection (Week 20 (2201) and
Week 14 (2202)). During the extension studies, lumbar
puncture was optional and only a few patients contributed
CSF (13 at Week 96 and 8 at Week 122 on open-label
treatment with CAD106). Decreases in CSF phospho-tau
concentrations from core study baseline were observed in
the extension studies. Baseline values at the start of
CAD106 open-label treatment (Week 56) were not avail-
able for comparison. For patients treated with CAD106
throughout the core and extension studies, the model
base (mixed-effects repeated-measures analysis) indi-
cated consistent results between studies. The least
squares mean change over time was −24.38 pg/ml (95%
confidence interval (CI): −28.25; −20.51) at Week 96 and
−21.29 pg/ml (95% CI: −26.42; −16.16) at Week 122. Of
note, the two patients who received placebo during
the core studies also showed a decrease in phospho-tau
from core study baseline when receiving CAD106 in the
extension studies.
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Farlow et al. Alzheimer's Research & Therapy  (2015) 7:23 Page 10 of 13Brain atrophy consistent with natural disease progres-
sion, and in line with published annual rates [22], was
observed across all studies and treatment groups. There
were no treatment-related findings with respect to total
brain volume or total ventricle volume.There were no treatment-related benefits with respect
to outcomes on clinical scales compared with placebo at
any time point. Patients generally demonstrated deteri-
oration on all assessment scales over the course of the
studies, consistent with the progressive nature of AD. Of
Farlow et al. Alzheimer's Research & Therapy  (2015) 7:23 Page 11 of 13those patients who continued in the extension studies,
mean (SD) change from baseline on the ADAS-Cog at
Week 52 was 5.6 (7.2) for CAD106 versus 5.0 (7.3) for
placebo; at Week 122 (all patients receiving CAD106),
the mean change from baseline was 12.8 (11.1).
Discussion
The results of these studies suggest that long-term treat-
ment with CAD106 is in line with the findings from the
phase I study and demonstrate that CAD106 is capable
of generating a consistent antibody response over the
course of seven injections [17].
The study population was representative of patients
with mild AD. In a review of ApoE status and its relation-
ship to AD, the frequency of ApoE4 carriers was estimated
to be 58% in the AD population versus 23% in the general
population [23]. The overall proportion of ApoE4 carriers
in these studies (>60%) is relevant when evaluating the
safety of CAD106 in ApoE4 carriers, who have been
reported to be at greater risk for ARIA-E following
treatment with the passive amyloid immunotherapy
bapineuzumab [23]. Throughout the studies reported
here, no patient met the criteria for ARIA-E and four pa-
tients met the criteria for ARIA-H. One patient who re-
ceived CAD106 during the core study experienced a
subarachnoid hemorrhage and was diagnosed with an
ICH 16 weeks later, approximately 5 months after re-
ceiving the last injection of CAD106.
Our findings support the safety and tolerability of
CAD106 observed in the phase I study [17]. There
were no unexpected safety findings related to treatment
with CAD106 and no occurrences of meningoencephalitis,
autoimmune disease, CNS inflammation or asymptomatic
vasogenic edema, in contrast to previous reports with Aβ
antibody therapies [18]. Although events related to cardiac
disorders were reported more frequently in CAD106-
treated patients versus placebo during the core studies, a
similar number of patients reported cardiac events in the
CAD106 open-label extension studies. No specific pattern
of disorder was identified, and the occurrence rate (<16%
overall) was in line with that expected in an elderly popu-
lation followed for up to 122 weeks.
The favorable tolerability and serological response of
i.m. versus s.c. administration seen in core study 2202
resulted in selection of i.m. administration for future
trials of CAD106.
Long-term administration of CAD106 was associ-
ated with a safety and tolerability profile similar to
the initial injections received during the core studies.
CAD106 was generally well tolerated, with most AEs
considered mild or moderate in severity and consist-
ent with that expected in an elderly population. They
were generally not considered related to study medica-
tion, with the exception of short-lasting and self-limitedinjection-related reactions, which were experienced by
most patients.
As observed in the phase I study [17], treatment with
CAD106 during the core studies induced an antibody re-
sponse against Aβ in the majority of patients. This find-
ing provides supporting evidence that CAD106 150 μg is
an effective dose for producing an antibody response.
Antibody titers at Week 8 (after second injection in
2201 or third injection in 2202) were similar across the
studies, indicating that the additional early injection at
Week 2 in 2202 did not contribute to the magnitude of
the immune response. Only two patients had a quanti-
fiable level of Aβ-specific IgGs in CSF, each at one
time point during the studies. The CSF : serum IgG ra-
tio was in line with the expected ratio for diffusion of
large molecules, such as antibodies, through the
blood–brain barrier [24]. A full mechanism supporting
the potential for peripheral antibodies targeting CNS
Aβ has not yet been elucidated. Despite the small
levels of Aβ-specific IgGs anticipated to reach the CSF,
these antibodies can exert a multitude of effects on
CNS Aβ [12,25].
Long-term treatment with CAD106 induced Aβ-specific
antibody titers similar to the initial response, but with a
prolonged time to decline, suggesting that antibody expos-
ure may be increased between injections. The observed
greater increase in total plasma Aβ1–40 with long-term
treatment could be explained by affinity maturation of the
Aβ-specific antibodies following repeated injections.
Indeed, affinity maturation profiles of the antibodies for
Aβ1–6 demonstrated a pronounced increase in affinity after
the third CAD106 injection, compared with after the sec-
ond injection in the same patient. However, the limited
sample size means that these results should be interpreted
with caution.
The absence of Aβ-specific T-cell responses in CAD106-
treated patients suggests that CAD106 does not induce a
T-cell-mediated immune response against Aβ, consistent
with previous findings from the phase I study [17].
This mechanism was involved in the autoimmune
meningoencephalitis observed with the full-length Aβ
protein, AN1792 [16]. Positive control T-cell activation
by the Qβ CAD106 carrier particle was shown in preclin-
ical studies with CAD106 [11], but our findings represent
the first time this response has been observed in humans.
Overall, the T-cell response to CAD106 treatment sup-
ports the favorable tolerability profile of CAD106, min-
imizing the likelihood of autoimmune reactions while
indicating its validity as an active immunization.
In addition to Aβ accumulation, AD pathology is charac-
terized by neurofibrillary tangles formed of hyperphosphory-
lated tau protein, which has been hypothesized to be a
downstream product of Aβ toxicity [26]. In the present
study, phospho-tau concentrations in the extensions were
Farlow et al. Alzheimer's Research & Therapy  (2015) 7:23 Page 12 of 13numerically lower than in the core studies, irrespective of
core study treatment. Although the relevance of these obser-
vations is difficult to assess in the absence of appropriate
reference measurements, the apparent decrease in phospho-
tau may be due to natural disease progression or a direct
treatment effect after more than 2 years of disease evolution
in patients with mild AD. Indeed, recent longitudinal
data have demonstrated that CSF biomarkers, including
phospho-tau, decrease in the later stages of AD [27,28].
No treatment-related differences were observed in brain
volume or in any of the AD clinical scale measurements.
However, the results on the clinical scales should be inter-
preted with caution, owing to small population sizes.
Continuous exposure to antibody titers through regular
injections, along with targeting earlier disease stages,
might increase the likelihood of positive effects on clinical
outcomes [17,29]. Indeed, recently published results mod-
eling Aβ accumulation using amyloid positron emission
tomography imaging demonstrated a sigmoidal pattern of
amyloid accumulation within the brain and suggested that
therapeutic strategies designed to reduce amyloid depos-
ition may be most effective if administered early in the
disease course [30,31]. A recent review summarized treat-
ment development in AD over the last 30 years and
highlighted the need for further detailed proof-of-concept
studies with anti-amyloid therapies [32].
Conclusions
The results of these studies indicate that long-term treat-
ment with CAD106 induced antibodies to Aβ and increased
Aβ1–40 levels in serum, suggesting that this approach can
achieve target engagement in the periphery. The favorable
safety profile of CAD106 observed in these studies supports
active immunization with Aβ1–6 and, combined with the
absence of a specific T-cell response against Aβ and the
ability to produce a sustained antibody response, suggests
that CAD106 may be a valuable therapeutic option in the
chronic treatment of AD. A 12-week interval between
CAD106 injections is currently being evaluated across seven
injections. This regimen is expected to result in continuous
exposure to higher antibody titers. Our data support the
continued investigation of active immunization strategies in
AD and offer promise for immunotherapy as a future treat-
ment option.
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